Beckman Medical's 'Magic Box': A Breakthrough Innovation for Recurrent Miscarriage Patients to Have Healthy Babies

May 2020, SuzhouThe First IVF Baby to Successfully Break the “Curse of Recurrent Miscarriage”celebrated her first birthday. The birth of this child holds extraordinary significance. More than two decades ago, Fangfang’s (a pseudonym) mother endured multiple recurrent miscarriages before successfully carrying Fangfang to term. However, when Fangfang married and began trying to conceive her own child, she too fell victim to the “curse” of recurrent miscarriage. In 2017, thanks to advanced medical technologies, the underlying cause of the recurrent miscarriages affecting both generations was finally identified. It turned out that Fangfang had inherited a specific chromosomal variant from her father—Chromosomal Balanced Translocation! In May 2019, with the assistance of the latest preimplantation genetic haplotyping (PGH) technology, this family finally broke free from the cycle of recurrent miscarriages, and a healthy newborn without the balanced chromosomal translocation gene was born.

Currently, the plight of families like Fangfang’s, who have been plagued by recurrent miscarriages for generations, is on the verge of being resolved. The domestically listed company Beikang Medical (stock code: 02170) has independently developed a productPGT-SR KitRelevant patents have been registered with the China National Intellectual Property Administration (CNIPA). This kit canEfficiently and accurately distinguish between embryos with normal chromosomal structure and those with translocations, effectively blocking the transmission of balanced translocations to offspring and increasing the likelihood of healthy pregnancies for patients.Yes, it will ensure that there are no more patients with miscarriages in the family.

The Chinese Expert Consensus on the Diagnosis and Treatment of Spontaneous Abortion (2020 Edition) states that the incidence of recurrent miscarriage in China is 1%–5%, with chromosomal abnormalities accounting for 11.7% of cases among couples experiencing recurrent miscarriage. Previously, patients were unable to identify the root causes of recurrent miscarriage or find effective solutions. Beikang Medical’s “Magic Box” is currently the world’s first innovative patent to break the “curse of recurrent miscarriage,” representing a beacon of domestic innovation in assisted reproductive technology.

As of December 2020, the Beikang Medical PGT-SR kit had completed testing on embryo samples from over 1,000 clinical cycles. Among these, 61.5% of the cycles yielded embryos with a completely normal karyotype, while 21.8% of the cycles yielded only carrier embryos. This indicates that through this testing, more than 60% of couples with balanced structural chromosomal abnormalities can select completely normal embryos for implantation, thereby completely blocking the transmission of chromosomal structural abnormalities within the family.

The cutting-edge “black tech” products introduced by Beikang Medical not only help patients with recurrent miscarriage identify the root causes but also enable the next generation to break free from the familial miscarriage “curse.”If this PGT-SR kit is successfully launched, it will become the world’s first product to detect chromosomal structural rearrangements using sequencing technology. Facing a large population suffering from recurrent miscarriages due to balanced translocations, Beikang Medical’s PGT-SR kit will gain a first-mover advantage in the market and breakthroughly drive the development of the fertility and reproductive health industries.

As the only listed innovative technology company in the domestic NGS niche sectorLeveraging its core strengths in the field of Preimplantation Genetic Testing (PGT)—with PGT-A (Preimplantation Genetic Testing for Aneuploidy) helping patients achieve successful pregnancies, PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) enabling eugenic outcomes, and PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements) helping patients overcome reproductive challenges—Beikang Medical has established a comprehensive product portfolio covering the entire reproductive lifecycle, including a three-tier prevention system spanning preconception, prenatal, and neonatal stages. Relying on leading-edge technology and robust products, Beikang Medical has repeatedly garnered favor from Hillhouse Investment and other prominent investors. Upholding its mission to “help more families have healthy babies,” Beikang Medical will continue to drive innovation in genetic technology, contribute to national eugenics efforts, and promote the development of China’s assisted reproductive technology industry, with the vision of ensuring that no child in China is born into a “difficult birth” situation.